CITANEST FORTE DENTAL (epinephrine bitartrate; prilocaine hydrochloride) by AstraZeneca is mechanism of action prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1965.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
CITANEST FORTE DENTAL is a local anesthetic combination injection containing prilocaine hydrochloride and epinephrine bitartrate, indicated for dental procedures. Prilocaine stabilizes neuronal membranes to inhibit ionic fluxes required for impulse conduction, producing local anesthetic effects. The epinephrine component provides vasoconstriction to prolong anesthetic duration and reduce systemic absorption.
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating shrinking team and focus on margin protection rather than growth initiatives.
Mechanism of Action Prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CITANEST FORTE DENTAL offers limited growth trajectory but provides stable, specialized experience in dental anesthesia commercialization and generic competition management. This role suits professionals seeking deep expertise in a niche market rather than high-growth career acceleration.
Worked on CITANEST FORTE DENTAL at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo